Period:

End of Day 1 Minute 5 Minute 10 Minute 15 Minute 30 Minute Hourly Weekly Monthly Yearly

NASDAQ, ARQL - Arqule Inc

We are a clinical-stage biotechnology company organized as a Delaware  corporation in 1993 and engaged in the research and development of innovative  cancer therapeutics. Our mission is to introduce novel products that act  selectively against cancer cells, target multiple tumor types and are well  tolerated by patients. We believe our clinical stage products represent  potential best-in-class or first-in-class small molecule candidates based on  highly differentiated mechanisms of action.  Our lead products, which are in clinical-stage testing, consist of: ARQ 197,  an orally administered inhibitor of the c-Met receptor tyrosine kinase; ARQ 501,  an intravenously administered novel activator of the cell's DNA damage response  mechanism mediated by the E2F-1 transcription factor; and ARQ 171, an  intravenously administered second generation activator of E2F-1.  ...

Read SEC Filing on NASDAQ.com »

Sector:	Consumer Durables
Industry:	Major Pharmaceuticals
P/E Ratio:	N/A
PEG Ratio:	N/A
EPS:	N/A
DivYield:	N/A
PtB:	7.11
PtS:	29.83
EBITDA:	N/A
Shares:	71.17M
Market Cap:	1.42B
52wk range:	3.15 - 20.45